Table 5.
Myeloablative conditioning
| Factor | n | Event | HR | HR low | HR upper | P |
|---|---|---|---|---|---|---|
| Relapse | ||||||
| Donor KIR haplotype | .77* | |||||
| AA | 490 | 153 | 1.00 | |||
| BX | 1060 | 306 | 0.97 | 0.82 | 1.16 | .77 |
| Cytogenetics | .0035 * | |||||
| Disease status | <.0001 * | |||||
| Early | 1148 | 337 | 1.00 | |||
| Intermediate | 370 | 104 | 1.09 | 0.86 | 1.38 | .4822 |
| Advanced | 32 | 18 | 3.93 | 1.90 | 8.14 | .0002 |
| ATG/alemtuzumab | .019 | |||||
| No ATG/alemtuzumab | 930 | 258 | 1.00 | |||
| ATG alone | 589 | 190 | 1.25 | 1.05 | 1.49 | .012 |
| Alemtuzumab alone | 31 | 11 | 1.43 | 0.85 | 2.40 | .18 |
| HLA-DP mismatch | .55 | |||||
| Fully matched | 267 | 84 | 1.00 | |||
| Mismatch | 1264 | 370 | 0.92 | 0.76 | 1.12 | .42 |
| Missing | 19 | 5 | 0.74 | 0.39 | 1.40 | .35 |
| Donor KIR centromeric regions | .23* | |||||
| AA | 744 | 237 | 1.00 | |||
| AB | 644 | 173 | 0.86 | 0.73 | 1.02 | .093 |
| BB | 162 | 49 | 1.03 | 0.77 | 1.37 | .86 |
| Cytogenetics | .0045 * | |||||
| Disease status | .0003 | |||||
| Early | 1148 | 337 | 1.00 | |||
| Intermediate | 370 | 104 | 1.09 | 0.86 | 1.38 | .50 |
| Advanced | 32 | 18 | 4.02 | 1.94 | 8.33 | .0002 |
| ATG/alemtuzumab | .016 | |||||
| No ATG/alemtuzumab | 930 | 258 | 1.00 | |||
| ATG alone | 589 | 190 | 1.26 | 1.06 | 1.50 | .010 |
| Alemtuzumab alone | 31 | 11 | 1.42 | 0.86 | 2.33 | .17 |
| HLA-DP mismatch | .57 | |||||
| Fully matched | 267 | 84 | 1.00 | |||
| Mismatch | 1264 | 370 | 0.93 | 0.77 | 1.12 | .44 |
| Missing | 19 | 5 | 0.74 | 0.39 | 1.41 | .36 |
| DFS | ||||||
| KIR B haplotype | .40 | |||||
| AA | 489 | 245 | 1.00 | |||
| BX | 1057 | 541 | 1.07 | 0.91 | 1.25 | .40 |
| HLA matched alleles | .0078 | |||||
| 7/8 | 245 | 141 | 1.00 | |||
| 8/8 | 1301 | 645 | 0.77 | 0.63 | 0.93 | .0078 |
| Cytogenetics | .0041 | |||||
| Donor age | .40 | |||||
| Disease status | <.0001 | |||||
| Early | 1147 | 566 | 1.00 | |||
| Intermediate | 369 | 196 | 1.20 | 1.03 | 1.40 | .019 |
| Advanced | 30 | 24 | 2.76 | 1.60 | 4.77 | .0003 |
| Recipient age, y | .0058 | |||||
| 20-29 | 194 | 78 | 1.00 | |||
| 30-39 | 251 | 119 | 1.23 | 0.97 | 1.55 | .084 |
| 40-49 | 367 | 175 | 1.26 | 0.95 | 1.65 | .10 |
| 50-59 | 467 | 247 | 1.41 | 1.11 | 1.77 | .0040 |
| ≥60 | 267 | 167 | 1.72 | 1.27 | 2.32 | .0005 |
| Recipient CMV status | .23 | |||||
| ATG/alemtuzumab | .81 | |||||
| No ATG/alemtuzumab | 929 | 474 | 1.00 | |||
| ATG alone | 586 | 295 | 1.02 | 0.89 | 1.17 | .79 |
| Alemtuzumab alone | 31 | 17 | 1.16 | 0.72 | 1.87 | .53 |
| HLA-DP mismatch | .78 | |||||
| Fully matched | 265 | 141 | 1.00 | |||
| Mismatch | 1262 | 635 | 0.95 | 0.81 | 1.11 | .49 |
| Missing | 19 | 10 | 0.93 | 0.59 | 1.46 | .74 |
| Donor KIR centromeric regions | .72 | |||||
| AA | 742 | 382 | 1.00 | |||
| AB | 643 | 321 | 0.99 | 0.84 | 1.17 | .93 |
| BB | 161 | 83 | 1.09 | 0.88 | 1.36 | .44 |
| HLA matched alleles | .0066 | |||||
| 7/8 | 245 | 141 | 1.00 | |||
| 8/8 | 1301 | 645 | 0.76 | 0.63 | 0.93 | .0066 |
| Cytogenetics | .0043 | |||||
| Donor age | .39 | |||||
| Disease status | <.0001 | |||||
| Early | 1147 | 566 | 1.00 | |||
| Intermediate | 369 | 196 | 1.20 | 1.03 | 1.40 | .021 |
| Advanced | 30 | 24 | 2.79 | 1.61 | 4.81 | .0002 |
| Recipient age, y | .0053 | |||||
| 20-29 | 194 | 78 | 1.00 | |||
| 30-39 | 251 | 119 | 1.23 | 0.97 | 1.55 | .082 |
| 40-49 | 367 | 175 | 1.26 | 0.96 | 1.65 | .098 |
| 50-59 | 467 | 247 | 1.41 | 1.12 | 1.77 | .0036 |
| ≥60 | 267 | 167 | 1.73 | 1.27 | 2.34 | .0004 |
| Recipient CMV status | .24 | |||||
| ATG/alemtuzumab | .83 | |||||
| No ATG/alemtuzumab | 929 | 474 | 1.00 | |||
| ATG alone | 586 | 295 | 1.03 | 0.89 | 1.18 | .73 |
| Alemtuzumab alone | 31 | 17 | 1.16 | 0.72 | 1.87 | .55 |
| HLA-DP mismatch | .80 | |||||
| Fully matched | 265 | 141 | 1.00 | |||
| Mismatch | 1262 | 635 | 0.95 | 0.81 | 1.11 | .51 |
| Missing | 19 | 10 | 0.94 | 0.60 | 1.47 | .77 |
Stratified variables: Karnofsky performance score. Poor risk cytogenetics significantly associated with risks of Relapse in RIC and MAC adjusted for other covariates. Bolded P values are independently significant P < .05.
*
Adjusted multivariate analysis for the end points shown stratified as indicated.